Pharmac reform in New Zealand is becoming an increasingly important policy question. When I arrived in New Zealand more than twenty years ago, it was widely accepted that, in an ideal world, every well-governed country would have a version of Pharmac.<\/p>\n
Without a doubt, Pharmac plays a critical role in New Zealand\u2019s health system. For three decades, it has operated within a tightly defined mandate to manage Pharmaceutical expenditure on behalf of the public. It has been successful, particularly in controlling costs and ensuring broad access to established medicines.<\/p>\n
However, the context in which Pharmac operates has changed significantly. Advances in medical science, shifting patient expectations, and increasing pressure on health systems globally are placing new demands on how medicines are assessed, funded and accessed. Against this backdrop, it is increasingly clear that the current structure is under strain. This is not an argument against Pharmac. Rather, it is an argument that the framework surrounding it has not kept pace with the realities of modern healthcare.<\/p>\n
At the heart of the issue is a structural tension between cost containment and health outcomes. Pharmac operates within a fixed budget, and its primary statutory objective is to secure the best health outcomes reasonably achievable from that budget. In practice, however, the fixed nature of the budget places a strong emphasis on cost control. Decisions are inevitably shaped by what can be afforded within a capped allocation, rather than by a broader assessment of value across the health system.<\/p>\n
This creates a disconnect. Medicines are not simply a cost to be managed; they are a form of investment that can reduce hospitalisations, improve productivity and enhance quality of life. When decisions are made within a constrained pharmaceutical budget, without sufficient integration with wider health system objectives, there is a risk that opportunities for long-term benefit are missed.<\/p>\n
Timeliness is another area where structural constraints are evident. New Zealand has long faced criticism for delays in accessing innovative medicines compared to other OECD countries. While comparisons must be made carefully, there is a persistent perception among clinicians, patients and industry stakeholders that the system is slow to respond to new therapeutic advances.
\nThese delays are not solely the result of individual decision-making processes. They are, in large part, a function of the system within which decisions are made. A capped budget, combined with increasing demand and the growing complexity of new medicines, inevitably leads to prioritisation decisions that can extend timelines.<\/p>\n
The result is not just a question of access, but of equity. Delays in funding can disproportionately affect patients with conditions for which new treatments represent a significant step forward. In these cases, time is not an abstract concept; it has real implications for health outcomes and quality of life.<\/p>\n
A further challenge lies in how value is assessed. Pharmac has developed robust processes for evaluating clinical and cost effectiveness, and these are widely respected. However, there is an ongoing debate about whether the current framework adequately captures the broader value of medicines, including their impact on the health system, workforce participation and societal wellbeing.<\/p>\n
In many jurisdictions, there is a growing recognition that medicines assessment should take a more holistic view. This does not mean abandoning cost-effectiveness principles, but rather complementing them with a wider understanding of value. In New Zealand, there is an opportunity to consider how such an approach might be incorporated into existing processes.
\nStakeholder relationships also warrant attention. Historically, Pharmac has been perceived by some as operating at arm\u2019s length from the communities it serves. While there have been efforts to improve engagement and transparency, there remains a sense among parts of the sector that the relationship can be adversarial.<\/p>\n
This matters because trust and collaboration are essential in a system where difficult decisions must be made. Clinicians, patient groups and industry stakeholders all have a role to play in contributing to a well-functioning medicines system. Strengthening these relationships is not about reducing independence; it is about ensuring that decisions are informed by a broad and credible evidence base, and that the rationale for those decisions is clearly understood.<\/p>\n
There is a case for better alignment between Pharmac\u2019s mandate and the wider objectives of the health system. This could involve a clearer recognition of how medicines investment contributes to overall system performance, including reducing pressure on hospitals and supporting preventive care.<\/p>\n
Consideration could also be given to how funding arrangements support long-term outcomes. A strictly capped budget may provide fiscal certainty, but it can also limit flexibility. Exploring mechanisms that allow for more dynamic investment, particularly in areas of high unmet need, could help address this constraint.<\/p>\n
There is an opportunity to evolve the framework for assessing value. Incorporating broader measures of impact, while maintaining rigorous evaluation standards, would better reflect the role that modern medicines play in improving health and societal outcomes.<\/p>\n
Finally, continued focus on transparency and engagement is critical. Ensuring that stakeholders understand how decisions are made, and have confidence in those processes, will strengthen the overall system.<\/p>\n
Clearly reform will not be straightforward. Pharmac operates within a complex policy and funding environment, and any changes must be carefully considered. However, maintaining the status quo is simply not an option.<\/p>\n
New Zealand\u2019s health system is under increasing pressure from demographic change, rising expectations and rapid advances in medical science. Medicines are a key part of the response to these challenges. Ensuring that the system through which they are assessed and funded is fit for purpose is not a marginal issue; it is central to the future performance of the health system.
\nReform, in this context, is not about weakening Pharmac. It is about enabling it to operate effectively within a modern, integrated health system, one that recognises medicines not simply as a cost, but as an investment in better health outcomes for all New Zealanders.<\/p>\n
Peter Boyes is a strategic communications adviser specialising in healthcare and public policy.\u00a0<\/em><\/p>\n","protected":false},"excerpt":{"rendered":" Pharmac reform in New Zealand is becoming an increasingly important policy question. When I arrived in New Zealand more than twenty years ago, it was widely accepted that, in an ideal world, every well-governed country would have a version of Pharmac. Without a doubt, Pharmac plays a critical role in New Zealand\u2019s health system. For […]<\/p>\n","protected":false},"author":1,"featured_media":300,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[20,21],"tags":[60,59,57,32,23,58],"class_list":["post-299","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-healthcare","category-public-policy","tag-health-reform","tag-health-systems","tag-healthcare-policy","tag-medicines-access","tag-pharmac","tag-public-health"],"yoast_head":"\n